Founder Partner

David Kauffmann founded EEP in 1999. He is a Board Director of AGC Biologics Inc. and Ropca Aps and an observer on the Board of Verdot.

He also held the position of Chairman of CMC Biologics prior to its successful sale to AGC Japan, Chairman of Azanta A/S, and Chairman of the management board of Aster Cephac SA. Both at CMC Biologics and at Aster Cephac, he was instrumental in building these two companies over 16 and 10 years, respectively, to international leaders in their field. At Azanta, he facilitated over 5 years a turn-around and the successful launch of a best in class therapeutic and was instrumental in the sale of the company to Norgine.

David co-founded and managed the 4 successful EEP Private Equity Funds for over 20 years through to their successful completion in 2020. Today, EEP is a private investment company managing and investing its own and affiliated capital.

David has invested in early stage, development and growth capital, particularly focusing on Healthcare Technology, Biologics and CGT manufacture, and Pharma Services companies.

Previously to EEP, he was a Junior Partner at CAI Capital Management Co., a Private Equity fund with offices in New York and Vancouver. Prior to working in Private Equity and Venture Capital, David worked for American Express Bank in London, New York, and Copenhagen. He holds an MBA from IMD in Lausanne, Switzerland, and a BSc from the Copenhagen School of Economics and Business Administration.



Neil is Partner, Chief Financial Officer and Chief Operating Officer of EEP. He is in charge of all financial and operational aspects of the organisation and is also responsible for investor communication, financial due diligence and monitoring the financial performance of the portfolio companies. Neil has also performed various operational roles for the EEP Portfolio companies including that of Interim CFO for Whatsonwhen for a period prior to its successful sale.

Prior to joining EEP in 2000, Neil was a Senior Manager for the Entrepreneurial Services Group at Ernst & Young (“EY”) in London and Chicago where he was responsible for working with Entrepreneurial Growth Companies: co-ordinating audits, acquisitions and flotations. He has over 30 years’ experience of advising and operating in the Private Equity industry.

Neil is a member of the Institute of Chartered Accountants in England and Wales, an Approved Person by the Financial Conduct Authority and holds a Masters Degree in Engineering and Management from Birmingham University.



Per Falholt founded his company Per Falholt Global R&D Advisory Services in 2016 and 21st.BIO in 2020 after many years working for Novo Nordisk and Novozymes.

Mr. Falholt joined Novo Nordisk in 1984 shortly after having obtained his M.Sc. in Chemical Engineering from Technical University of Denmark in 1983. In Novo Nordisk he held various positions in Research & Development from scientist to director level leading to a position as Senior Vice President for Enzyme Development and Application until he continued on to Novozymes in 2000; first as a Global Manager and then as the Executive Vice President for Research and Development.

Over the years, Per Falholt has been a driving force in multiple initiatives to foster talents and enhance science education in Denmark; among these is LIFE, a nonprofit project to establish a world-class learning laboratory within science, technology, engineering and mathematics supported by the Novo Nordisk Foundation.

Besides holding numerous positions of trust within the biotech area at boards, councils and committees Per Falholt chairs the Board of Governors at the DHI foundation, Curasight and Universe.